- Q2 Revenue up
55%, Gross Profit up 128% and Net Income up 1014%
-
TORONTO and DUREN, Germany, Aug. 24,
2022 /CNW/ - GBLT Corp. (TSXV: GBLT)
("GBLT" or the "Company") is pleased to announce its
second quarter for the three-month and six-month period ended
June 30th, 2022.
"With the legacy priced contracts behind us, we have experienced
a much improved second quarter with increases in both revenue and
gross margins," said Dr. Thilo
Senst, CEO of GBLT. "We have also posted an increase in the
bottom line as net income has improved both YTD and comparing
quarters from 2021. We are confident that the momentum will
continue into the second half as we expand our high margin product
lines into various regions globally. We remain very optimistic
about the future outlook, as the company has been actively
addressing the higher logistic costs and inflation with price
adjustments on our energy storage products, while focusing on
growing the high margin Dr. Senst healthcare product lines and our
renewable energy products that will drive GBLT's bottom line growth
for the foreseeable future."
- Revenue for the three-month period ended June 30th, 2022, increased by 55%
to €10.06 million ($13.18
million CAD) compared to €6.50 million ($8.50 million CAD) for the same period in 2021
and increased by 25% compared to Q1 2022. The increase in revenue
was due to increase in customer demand for the company's healthcare
products, addition of new customer and the expansion of the
company's solar product line.
- Gross margin for the three-month period ended June 30th, 2022, improved to 18%
compared to 12% for the same period in 2021. The increase was due
to flexible pricing and focusing on the higher margin product
lines.
- Gross profit for the three-month period ended June 30th, 2022, increased by 128% to
€1.82 million ($2.38 million CAD)
compared to €0.8 million ($1.05
million CAD) for the same period in 2021 and increased by
181% compared to Q1 2022.
- Operating expenses for the three-month ended June 30th, 2022, was €1.05 million
($1.38 million CAD) compared to €0.74
million ($0.97 million CAD) in Q2
2021 and €0.66 million ($0.86
million) in Q1 2022.
- Net income (Loss) for the three-month period ended June 30th, 2022, increased by 1014% to
€0.78 million ($1.02 million CAD)
compared to €0.07 million ($0.09
million CAD) in Q2 2022 and increased by 4475% compared to
Q1 2022.
- Adjusted EBITDA for the three-month period ended June 30th, 2022, increased by 622% to
€0.91 million ($1.19 million CAD)
compared to €0.13 million for the same period in 2021 and increased
by 1266% compared to Q1 2022.
Year to Date
- Revenue for the first half of 2022 increased by 18% to €18.1
million ($23.7 million CAD) compared
to €15.3 million ($20.04 million CAD)
in 2021. The increase in revenue was due to increase in customer
demand for the company's healthcare products, addition of new
customer and the expansion of the company's solar product
line.
- Gross margin for the first half of 2022 improved to 14%
compared 11% for the same period in 2021. The increase was due to
flexible pricing and focusing on the higher margin product
lines.
- Gross profit for the first half of 2022 increased by 49% to
€2.48 million ($3.25 million CAD)
compared to €1.66 million ($2.17
million CAD) in 2021.
- Operating expenses for the first half of 2022 was €1.71 million
($2.24 million CAD) compared €1.20
million ($1.56 million CAD) in
2021.
- Net Income for the first half of 2022 increased by 61% to €0.76
million ($0.99 million CAD) compared
to €0.47 million ($0.61 million CAD)
in 2021.
- Adjusted EBITDA for the first half of 2022 increased by 58% to
€1.04 million ($1.36 million CAD)
compared to €0.66 million ($0.87
million CAD) in 2021.
EBITDA
|
|
Three months ended
June 30,
|
|
Six months ended
June 30,
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
Net Income for the
Period
|
€
|
779,080
|
€
|
65,230
|
€
|
761,272
|
€
|
466,961
|
Depreciation
|
|
27,935
|
|
12,344
|
|
41,287
|
|
22,208
|
Interest and financing
fees
|
|
103,733
|
|
47,785
|
|
175,512
|
|
77,237
|
EBITDA
|
|
910,748
|
|
125,359
|
|
978,071
|
|
566,406
|
Bad debt
expense
|
|
|
|
|
|
109,854
|
|
98,677
|
Currency exchange gain
(loss)
|
|
(1,608)
|
|
(1,080)
|
|
(51,786)
|
|
(4,432)
|
Share based
payments
|
|
-
|
|
1,644
|
|
-
|
|
5,137
|
Adjusted
EBITDA
|
€
|
909,140
|
€
|
125,923
|
€
|
1,036,139
|
€
|
665,788
|
EBITDA
(CAD)
|
|
Three months ended
June 30,
|
|
Six months ended
June 30,
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
Net Income for the
Period
|
$
|
1,020,595
|
$
|
85,451
|
$
|
997,266
|
$
|
611,719
|
Depreciation
|
|
36,595
|
|
16,171
|
|
54,086
|
|
29,092
|
Interest and financing
fees
|
|
135,890
|
|
62,598
|
|
229,921
|
|
101,180
|
EBITDA
|
|
1,193,080
|
|
164,220
|
|
1,281,273
|
|
741,992
|
Bad debt
expense
|
|
|
|
|
|
143,909
|
|
129,267
|
Currency exchange gain
(loss)
|
|
(2,106)
|
|
(1,415)
|
|
(67,840)
|
|
(5,806)
|
Share based
payments
|
|
|
|
2,154
|
|
|
|
6,729
|
Adjusted
EBITDA
|
$
|
1,190,973
|
$
|
164,959
|
$
|
1,357,342
|
$
|
872,182
|
|
Source: Bank of Canada Exchange Rate at 2022-08-18
rate of €1.31 per $1.00 CAD
|
|
https://www.bankofcanada.ca/rates/exchange/daily-exchange-rates/
|
About GBLT:
GBLT Corp., through its operating company, GBT GmbH, designs,
manufactures and supplies mobile storage, and battery solutions.
GBLT is also a leading provider of renewable energy solutions via
its solar division, participating in the rapidly growing solar
energy market. In addition, the Company offers consumer healthcare
and wellness products to some of the largest retail chains across
the globe. GBT is also an official licensee for AGFAPHOTO mobile
energy products. The Company's branded healthcare and wellbeing
products are primarily sold throughout Europe under Dr. Senst brand.
For more information, please visit www.gbt-international.com
and www.gbltcorp.com.
Forward-Looking
Information
Certain statements in this news release, which are not
historical in nature, constitute "forward looking statements"
within the meaning of that phrase under applicable Canadian
securities law. These statements include, but are not limited to,
statements or information concerning the Company's proposed
activities under the Agreement, the Company's ability to achieve
sales, commercial or otherwise, from its products, and the
expectations of the Company regarding funding payments due pursuant
to the Agreement. These statements reflect management's current
assumptions and expectations and by their nature are subject to
certain underlying assumptions, known and unknown risks and
uncertainties and other factors which may cause actual results,
performance or events to be materially different from those
expressed or implied by such forward looking statements. Except as
required pursuant to applicable securities laws, the Company will
not update these forward-looking statements to reflect events or
circumstances after the date hereof. More detailed information
about potential factors that could affect financial results is
included in the documents filed from time to time with the Canadian
securities regulatory authorities by the Company. Readers are
cautioned not to place undue reliance on forward looking
statements.
Neither the TSX Venture Exchange nor its
Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE GBLT Corp.